文献速递治疗药物监测与药物基因组学药物不良反应与药物警戒

305例SLE flare患者治疗依从性前瞻性国际研究:药物浓度与自评问卷评估

A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires.
PubMed 文献 · Clin Pharmacol Ther · 2018-09-02

该国际前瞻性研究纳入305例系统性红斑狼疮 flare 患者,用羟氯喹(HCQ)血药浓度(HCQ<200 ng/ml或去乙基氯喹不可测)和自评问卷(MASRI<80%)评估不依从。药物浓度定义18.4%患者为严重不依从,问卷分类23.4%为不依从;两法与医生评估相关性中等,提示治疗药物监测在此场景有用。

要点

  • 药物浓度定义18.4%SLE flare患者严重不依从。
  • 问卷分类23.4%患者不依从,与药物浓度捕捉不同模式。
  • 年轻、未用激素、高BMI、失业与药物浓度不依从相关。

核心结论

  • SLE flare患者中严重不依从常见,药物浓度可识别中断或 erratic 服药。
  • 医生常漏诊不依从且患者低报,支持在此场景使用治疗药物监测。

研究设计与样本

  • 前瞻性国际研究,纳入305例SLE flare患者。
  • 用HCQ血药浓度(HCQ<200 ng/ml或去乙基氯喹不可测)和自评问卷(MASRI<80%)评估不依从。

主要发现

  • 药物浓度定义18.4%患者为严重不依从。
  • 问卷分类23.4%患者为不依从。
  • 问卷、药物浓度与医生评估间相关性中等。
  • 多变量分析中年轻、未用激素、较高BMI和失业与药物浓度不依从相关。
  • 问卷多捕捉较少漏服,药物浓度识别严重不依从(中断或 erratic 服药)。

关键数值与推荐

  • 药物浓度不依从:HCQ<200 ng/ml或去乙基氯喹不可测。
  • 问卷不依从:MASRI<80%。

临床怎么用

  • 对SLE flare患者可考虑HCQ血药浓度监测以识别严重不依从。
  • 不应仅依赖患者自评问卷或医生判断评估依从性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Nonadherence to treatment is a major cause of lupus flares. Hydroxychloroquine (HCQ), a major medication in systemic lupus erythematosus, has a long half-life and can be quantified by high-performance liquid chromatography. This international study evaluated nonadherence in 305 lupus patients with flares using drug levels (HCQ < 200 ng/ml or undetectable desethylchloroquine), and self-administered questionnaires (MASRI < 80%). Drug levels defined 18.4% of the patients as severely nonadherent. In multivariate analyses, younger age, nonuse of steroids, higher body mass index, and unemployment were associated with nonadherence by drug level. Questionnaires classified 23.4% of patients as nonadherent. Correlations between adherence measured by questionnaires, drug level, and physician assessment were moderate. Both methods probably measured two different patterns of nonadherence: self-administered questionnaires mostly captured relatively infrequently missed tablets, while drug levels identified severe nonadherence (i.e., interruption or erratic tablet intake). The frequency with which physicians miss nonadherence, together with underreporting by patients, suggests that therapeutic drug monitoring is useful in this setting. (Trial registration: ClinicalTrials.gov: NCT01509989.).

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Costedoat-Chalumeau N, Houssiau F, Izmirly P, et al. A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires. Clin Pharmacol Ther. 2018. PMID: 30079582. doi:10.1002/cpt.1194

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。